# Daniel J Drucker

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/808103/publications.pdf

Version: 2024-02-01

| 25 | 1,805 | 471509 | 580821 |
|---|---|---|---|
| papers | citations | 17 h-index | 25 g-index |

| 25 | 25 | 25 | 2893 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism, 2022, 57, 101351. | 6.5 | 119 |
| 2 | Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation. Endocrine Reviews, 2021, 42, 101-132. | 20.1 | 115 |
| 3 | Transforming type 1 diabetes: the next wave of innovation. Diabetologia, 2021, 64, 1059-1065. | 6.3 | 8 |
| 4 | Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning. Cell Metabolism, 2021, 33, 479-498. | 16.2 | 179 |
| 5 | Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Molecular Metabolism, 2021, 46, 101090. | 6.5 | 150 |
| 6 | TCF7 is not essential for glucose homeostasis in mice. Molecular Metabolism, 2021, 48, 101213. | 6.5 | 1 |
| 7 | Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide. JCI Insight, 2021, 6, . | 5.0 | 23 |
| 8 | Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. Med, 2021, 2, 1203-1230. | 4.4 | 17 |
| 9 | Advances in oral peptide therapeutics. Nature Reviews Drug Discovery, 2020, 19, 277-289. | 46.4 | 354 |
| 10 | Proglucagon-Derived Peptides, Glucose-Dependent Insulinotropic Polypeptide, and Dipeptidyl Peptidase-4-Mechanisms of Action in Adipose Tissue. Endocrinology, 2020, 161, . | 2.8 | 15 |
| 11 | Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans. Nature Communications, 2020, 11, 3766. | 12.8 | 43 |
| 12 | The gut hormone receptor GIPR links energy availability to the control of hematopoiesis. Molecular Metabolism, 2020, 39, 101008. | 6.5 | 12 |
| 13 | L-Cell Differentiation Is Induced by Bile Acids Through GPBAR1 and Paracrine GLP-1 and Serotonin Signaling. Diabetes, 2020, 69, 614-623. | 0.6 | 54 |
| 14 | Coronavirus Infections and Type 2 Diabetesâ€"Shared Pathways with Therapeutic Implications. Endocrine Reviews, 2020, 41, . | 20.1 | 314 |
| 15 | Intestine-selective reduction of Gcg expression reveals the importance of the distal gut for GLP-1 secretion. Molecular Metabolism, 2020, 37, 100990. | 6.5 | 39 |
| 16 | Loss of Glp2r signaling activates hepatic stellate cells and exacerbates diet-induced steatohepatitis in mice. JCI Insight, 2020, 5, . | 5.0 | 11 |
| 17 | Hematopoietic cellâ€“ versus enterocyte-derived dipeptidyl peptidase-4 differentially regulates triglyceride excursion in mice. JCI Insight, 2020, 5, . | 5.0 | 7 |
| 18 | Localization of Glucagon-Like Peptide-2 Receptor Expression in the Mouse. Endocrinology, 2019, 160, 1950-1963. | 2.8 | 33 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome. ACS Pharmacology and Translational Science, 2019, 2, 134-142. | 4.9 | 28 |
| 20 | Hepatic Glucagon Receptor Signaling Enhances Insulin-Stimulated Glucose Disposal in Rodents. Diabetes, 2018, 67, 2157-2166. | 0.6 | 44 |
| 21 | Sitagliptin Accelerates Endothelial Regeneration after Vascular Injury Independent from GLP1 Receptor Signaling. Stem Cells International, 2018, 2018, 1-11. | 2.5 | 14 |
| 22 | The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications. Diabetes, 2018, 67, 1710-1719. | 0.6 | 64 |
| 23 | Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21. Diabetes, 2018, 67, 1773-1782. | 0.6 | 54 |
| 24 | Î²-Cell Inactivation of Gpr119 Unmasks Incretin Dependence of GPR119-Mediated Glucoregulation. Diabetes, 2017, 66, 1626-1635. | 0.6 | 25 |
| 25 | Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1Î±1-67 in Patients With Type 2 Diabetes. Diabetes Care, 2017, 40, 1073-1081. | 8.6 | 82 |